** Shares of Coherus BioSciences CHRS.O jump 20% to $1.64 premarket
** Co to divest its biosimilar Udenyca in a deal with India's Intas Pharmaceuticals for up to $558.4 million, including an upfront payment of $483.4 million
** Udenyca is the copycat version to Amgen Inc's AMGN.O infection-fighting treatment Neulasta
** CHRS plans to focus on its approved cancer treatment Loqtorzi
** CHRS plans to use proceeds from the deal to fund development of combination therapies with Loqtorzi and repay the company's $230.0 million in existing convertible notes due April 2026
** Up to last close, CHRS down ~59% YTD
(Reporting by Mariam Sunny in Bengaluru)
((Mariam.ESunny@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.